Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement

Managed access agreements provide a crucial mechanism whereby real-world data can be collected systematically to reduce uncertainty around available clinical and economic data, whilst providing the opportunity to identify patient sub-populations who are most likely to benefit from a new treatment. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Stevens, Bob, Kenny, Tom, Thomas, Sophie, Morrison, Alexandra, Jarrett, James, Jain, Mohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Position Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467187/
https://www.ncbi.nlm.nih.gov/pubmed/34563214
http://dx.doi.org/10.1186/s13023-021-01876-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467187/
https://www.ncbi.nlm.nih.gov/pubmed/34563214
http://dx.doi.org/10.1186/s13023-021-01876-4

Ejemplares similares